Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study

PURPOSE: Most patients with gastrointestinal stromal tumor (GIST) have activating mutations in KIT/PDGFRA and are initially responsive to tyrosine kinase inhibitors (TKI). The acquisition of secondary mutations leads to refractory/relapsed disease. This study reports the results of an analysis from...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Sebastian, Heinrich, Michael C., George, Suzanne, Zalcberg, John R., Serrano, César, Gelderblom, Hans, Jones, Robin L., Attia, Steven, D'Amato, Gina, Chi, Ping, Reichardt, Peter, Meade, Julie, Su, Ying, Ruiz-Soto, Rodrigo, Blay, Jean-Yves, von Mehren, Margaret, Schöffski, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401492/
https://www.ncbi.nlm.nih.gov/pubmed/34503977
http://dx.doi.org/10.1158/1078-0432.CCR-21-1864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401492/
https://www.ncbi.nlm.nih.gov/pubmed/34503977
http://dx.doi.org/10.1158/1078-0432.CCR-21-1864

Ejemplares similares